Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rhPDGF-BB gel for diabetic foot ulcers
ChiCTR2200061652Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of becaplermin in diabetic foot ulcer (DFU) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Safety and tolerability. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
becaplermin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on ChiCTR2200061652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061652.